While the clinical dementia findings did not reach statistical significance, they were the first to provide a hint that early ...

Hollywood has in recent years been undergoing a much-needed, long-awaited transformation in its portrayals of women and ...

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a new study. The ...

Dementia is caused by different diseases that affect the brain, the most common being Alzheimer’s. Frontotemporal dementia, also known as FTD, is a rare type of dementia. It is thought to account for ...

Investigators said that the OLE study showed Roche’s gantenerumab dropped the risk of developing Alzheimer's symptoms by 50%.

A study of Roche's anti-amyloid drug gantenerumab has suggested that early treatment to remove amyloid plaques from the brain ...

Eli Lilly (NYSE: LLY) has been around for almost 150 years, finding ways to innovate and grow. The next largest healthcare ...

Gantenerumab shows promise in preventing Alzheimers disease after past failures Gantenerumab demonstrates significant ...

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in ...

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s ...

Circular Genomics, originally founded in New Mexico, and who specializes in circular RNA (circRNA) biomarkers for precision ...